In Brief: Medtronic/Regeneron
This article was originally published in The Gray Sheet
Medtronic/Regeneron: Firms enter agreement to co-develop "a family of therapeutics for central nervous system diseases and disorders" using experimental Regeneron compounds and Medtronic delivery systems. The initial project under the agreement will be development of Regeneron's Axokine, delivered using a Medtronic implantable pump, for treatment of Huntington's disease. Under terms of the deal, Medtronic has purchased 460,500 shares of Regeneron common stock for $10 mil. and has acquired five-year warrants to buy another 107,400 shares for $21.72 per share. Regeneron will conduct preclinical development of Axokine and "retains all rights to manufacture and commercialize" the drug. Medtronic, which will make milestone payments to Regeneron during the drug's development, retains rights to manufacture and sell the delivery devices, and will receive royalties on sales of drugs developed under the pact...
You may also be interested in...
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
Russia says it will make the first deliveries of its $10-per-dose Sputnik V vaccine in January, while international regulators say vaccine trials should continue for as long as possible to generate longer-term evidence on their benefits and risks. A UK research body has stressed that drugs repurposed for COVID-19 also need to undergo thorough safety and efficacy testing as reports suggest the UK regulator could approve a vaccine within days.
Skin hygiene is one of several categories where Edgewell Personal Care has a “right to win" after 18 months of renovations, according to the company’s 20 November Investor Day presentation. The firm has doubled its production capacity and has plans for a “full suite” of product innovation to build on Wet Ones’ 60% growth in fiscal 2020.